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Abstract 
Background: S-222611 is a reversible inhibitor of EGFR, HER2 and HER4 with 
preclinical activity in models expressing these proteins.  We have performed a Phase 
I study to determine safety, maximum tolerated dose (MTD), pharmacokinetic profile 
(PK) and preliminary efficacy in patients with solid tumours expressing EGFR or 
HER2.   
Methods: We conducted this first-in-patient study at 3 sites in the UK. Subjects had 
advanced tumours not suitable for standard treatment, expressing EGFR and/or 
overexpressing HER2 using immunohistochemistry, and/or with amplified HER2 
using FISH. Daily oral doses of S-222611 were escalated from 100mg to 1600mg. 
Full plasma concentration profiles for drug and metabolites were obtained. Optional 
paired tumour biopsies were obtained for analysis of pharmacodynamic biomarkers. 
Findings: 33 patients received S-222611. It was well tolerated, and the most 
common toxicities, almost all mild (grade 1 or 2), were diarrhoea, fatigue, rash and 
nausea. Only two dose-limiting toxicities occurred (diarrhoea and rash), which 
resolved on interruption.  Maximum tolerated dose was not reached.  Plasma 
exposure increased with dose up to 800mg, exceeding levels eliciting pre-clinical 
responses.  The plasma terminal half-life was more than 24 h, supporting once daily 
dosing. Responses were seen over a wide range of doses, including one complete 
clinical response in a patient with HER2-positive breast carcinoma previously treated 
with lapatinib and trastuzumab. Six partial responses were seen in EGFR- and/or 
HER2-positive oesophageal, breast and renal cancers, with prolonged stable disease 
in a further two patients (clinical benefit in 27%). Four patients have remained on 
treatment for more than 12 months.  
Interpretation: Continuous daily oral S-222611 is well tolerated, and has broad and 
significant antitumour activity. The recommended Phase 2 dose, based on PK and 
efficacy, is 800mg/day. 
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Introduction 
Dysregulation of signaling via the ERBB receptor tyrosine kinase family is one of the 
most common oncogenic drivers in epithelial tumours (1).  The members of this 
family, epidermal growth factor receptor (EGFR; ERBB1) and human epidermal 
growth factor receptors 2-4 (HER2-4), interact with each other through homo- and 
heterodimerization, leading to activation of their intracellular tyrosine kinase domains. 
Small molecule reversible inhibitors targeting EGFR are most active in tumours 
driven by activating EGFR mutations (2, 3).  However, in most other epithelial 
tumours the complexity of signaling mediated by the various ERBB receptors 
predicts that specific inhibition of a single family member may be insufficient to gain 
sustained control of neoplastic proliferation (1).  A second generation of ERBB 
inhibitors has been developed with broader specificity, but these have modest activity 
in all but a narrow range of diseases (4, 5).  Earlier generations of ERBB inhibitors 
are also associated with significant on-target toxicities, especially rash and diarrhoea, 
at active doses, and with fatigue, which can be problematic with chronic treatment (6).  
New, more potent, broad spectrum, less toxic ERBB inhibitors are required.  
S-222611, an oral agent, is a novel, reversible, selective and potent inhibitor of 
EGFR, HER2 and HER4 kinases.  S-222611 inhibits the ERBB kinases with IC50 
values for EGFR, HER2 and HER4 of 1.5 nM, 7.2 nM and 2.5 nM, respectively.  In 
pre-clinical studies, S-222611 has activity against EGFR- and HER2-expressing 
human cell lines and xenografts, including a model of breast cancer brain and bone 
metastases (manuscript in preparation). In healthy male volunteers, single doses up 
to 400mg (the maximum tested) were well tolerated with an adverse event profile 
indistinguishable from placebo.  Systemic exposure (Cmax and AUC0-inf) was 
proportional to dose and mean t1/2λz ranged from 20.8 to 25.6 h, independent of dose.  
Following administration of a 100mg tablet, Cmax and AUC0-nf were 12% and 30% 
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higher in the fed than in the fasted state, respectively.  The data support once daily 
dosing without an important effect of the time of dosing relative to meals.     
These encouraging data and the unmet need for more effective and better tolerated 
ERBB inhibition led us to conduct a Phase I dose-escalation study of S-222611 in 
patients with advanced solid tumours expressing EGFR and/or HER2.  The primary 
objectives were to evaluate safety and define the MTD of S-222611 when 
administered in a continuous, once-daily dosing schedule.  Secondary objectives 
included pharmacokinetic (PK) evaluation of S-222611, preliminary assessment of 
anti-tumour efficacy, and assessment of pharmacodynamic markers in tumour 
biopsies. 
Patients and Methods 
Study population and drug administration 
This was a Phase I, open-label, dose-escalation study of continuous once-daily oral 
treatment with S-222611 conducted at three centres from July 2010 to November 
2012.  Eligible patients had histologically confirmed solid tumours not amenable to 
established treatments, expressing EGFR (1+ to 3+) and/or overexpressing HER2 
using immunohistochemistry, and/or with amplified HER2 using FISH (3+ or 2+ with 
amplification).  Colorectal cancer patients with KRAS mutation were excluded.  Other 
eligibility criteria included written informed consent; age ≥ 18 years; Eastern 
Cooperative Oncology Group (ECOG) performance status 0-1; completion of 
previous anticancer therapy at least 4 weeks before study entry with recovery from 
all previous therapy-related toxicities to Common Terminology Criteria for Adverse 
Events v4.0 (CTCAE) Grade ≤1; adequate bone marrow, renal, hepatic and left 
ventricular function; and no concomitant anticancer or investigational drug.  Patients 
were excluded if they had active autoimmune or infectious disease; a gastrointestinal 
disorder that could interfere with the absorption of oral study drug; needed treatment 
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with a strong CYP3A4 inhibitor or inducer; had uncontrolled brain metastasis; were 
sexually active and unwilling to use effective methods of contraception; pregnant or 
breast feeding.  The study was approved after review by the relevant regulatory and 
independent ethics committees, and conducted in accordance with the Declaration of 
Helsinki and International Conference on Harmonization (ICH) Good Clinical Practice 
(GCP).  
S-222611 (Shionogi & Co. Ltd, Osaka, Japan) was administered as a single dose on 
Day 1 with continuous daily dosing from Day 8.  All doses were administered as 
tablets containing 100mg S-222611, within 30 minutes of eating breakfast.  Based on 
the concentrations demonstrating efficacy in preclinical tumour models and toxicity 
studies, and the tolerability and pharmacokinetics obtained with single doses in 
healthy volunteers, a continuous daily dose of 100mg was selected as the starting 
dose for escalation in patients with solid tumours. Subsequent dose levels planned 
were 200, 400, 800, 1200 and 1600mg daily. Dose reduction was allowed following 
dose limiting toxicity (DLT), provided the toxicity had improved to less than Grade 1 
and the dose interruption did not exceed 14 days.  Treatment continued until disease 
progression, unacceptable toxicity, or withdrawal of patient’s consent. 
Dose escalation followed a 3+3 design with cohort expansion to six patients if one 
DLT was reported during the first 28-day cycle.  The MTD was defined as the highest 
dose at which DLT occurred in no more than one of 6 patients during the first cycle.  
The protocol required that if two DLTs were observed at any dose level, dose 
escalation was to stop and the preceding cohort expanded to include at least six 
patients.  Safety and PK data were reviewed regularly by a data monitoring 
committee, which made recommendations regarding dose selection. After the dose 
had been escalated to 1600mg, all cohorts receiving doses of ≥400mg were 
expanded to 6 patients to obtain additional PK data. 
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Study procedures 
Screening tests at baseline included physical examination, computerized tomography 
with measurement of target and non-target lesions using Response Evaluation 
Criteria in Solid Tumours (RECIST) version1.1, complete blood count, clotting, tests 
of renal and liver function, electrocardiogram (ECG), left ventricular ejection fraction 
(LVEF) by echocardiogram or multiple-gated acquisition (MUGA) scan, and 
ophthalmic examination because of corneal opacification observed in preclinical 
toxicity studies.  ECG telemetry was performed for 8h following the first dose. All 
adverse events and laboratory variables were assessed using the CTCAE version 
4.0.  LVEF was evaluated after 4 and 8 weeks, and subsequently at intervals of 8 
weeks.  Ophthalmic examination was repeated after 4 weeks, and subsequently if 
clinically indicated. Other safety assessments were repeated at baseline, on Days 2, 
3, 5, 8, 15, and 22, at weekly intervals for a further 5 weeks, and then every 2 weeks. 
Pharmacokinetic analysis 
Blood was drawn for measurement of plasma concentrations of S-222611 and its 
active dealkylated and lactam metabolites before and 2, 4, 6, 12, 24, 48 and 96h 
after the first single dose on Day 1, and directly before daily drug administration on 
Days 8, 15 and 22.  An additional 24h PK profile was performed after 21 days of 
repeat dosing, with samples collected before and 2, 4, 6, 12 and 24h after drug 
administration.  
Plasma concentrations of S-222611 and metabolites were analyzed by a validated 
liquid chromatography tandem mass spectrometry (LC-MS/MS) method (Charles 
River Laboratories).  The quantification range for S-222611 was 0.5–5.0 ng/mL 
(undiluted plasma).  Assay performance was assessed by back-calculation of 
calibration standards, tabulation of the standard curve fit function parameters, and 
measurement of quality control samples. Standard non-compartmental analysis was 
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performed to estimate the PK parameters for S-222611 and metabolites based on 
plasma concentration (WinNonlin® Professional 5.2 or SAS® Version 9.2).  
The following PK parameters were estimated: maximum observed plasma 
concentration (Cmax), time from dosing to Cmax (Tmax), area under the plasma 
concentration versus time curve from time zero extrapolated to infinity (AUC0-inf), 
apparent total body clearance (CL/F), apparent volume of distribution (Vz/F) and 
terminal half-life (t½λz) for single dose; Cmax, Tmax, area under the plasma 
concentration versus time curve during a dosing interval (AUCτ), average plasma 
concentration during a dosing interval (Cav), and fluctuation index ((Cmax – Cmin) / Cav) 
(FI) over a dosing interval for repeat dosing. 
Tumour evaluation and pharmacodynamic assessment 
Tumour response was assessed according to RECIST version 1.1 (7) at intervals of 
8 weeks.  Efficacy parameters included complete response (CR), partial response 
(PR), duration of response (time from CR or PR to disease progression), and 
progression-free survival (PFS; time from first treatment to disease progression, 
death, or censoring date).  Tumour biopsies were obtained, where accessible, for 
analysis of ERBB signaling components at baseline and after 1 month of treatment. 
Role of the funding source 
This study was funded by the study sponsor (Shionogi & Co., Ltd) and monitored by 
a contract research organisation (Quintiles). The contract research organisation 
collated all data and the authors performed the data analysis. The report was written 
by JS, with contribution from all authors, who included employees of Shionogi & Co., 
Ltd. The corresponding author had full access to all the data in the study and had 
final responsibility for the decision to submit for publication. 
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Results 
A total of 33 patients were included in the dose escalation; all contributed to the 
safety analysis.  Daily dose levels studied were 100mg (n=5), 200mg (n=3), 400mg 
(n=6), 800mg (n=6), 1200mg (n=6), and 1600mg (n=7).  Patient characteristics are 
shown in Table 1.   
Safety and tolerability  
Of 33 patients, 29 completed the single dose and first 3 weeks of repeat dosing, and 
were evaluable for dose-limiting toxicity. Five patients discontinued early, due to 
disease progression or clinical deterioration (n=4) or withdrawn consent (n=1).  All 33 
(100 %) patients experienced at least one adverse event (AE), irrespective of 
relationship to study drug. Table 2 summarizes all treatment-related AEs of any 
grade occurring in 3 or more patients, and all Grade 3 treatment-related AEs. There 
were no Grade 4 toxicities or treatment-related deaths. 
In general, S-222611 was very well tolerated. The majority of AEs were Grade 1/2, 
and no significant hematological or biochemical toxicity was observed. The most 
frequently reported toxicities were diarrhoea (n=26, 79 %; 70% Grade 1/2), fatigue 
(n=20, 61 %), rash (n=19, 58%), and nausea (n=17, 52 %). Diarrhoea was generally 
self-limiting or effectively controlled with loperamide.  Although Grade 3 diarrhoea did 
occur at or above 1200mg, this responded to dose interruption and did not recur on 
re-challenge with dose reduction. Fatigue was commonly reported, but there was no 
trend with dose in its frequency or severity. Grade 1/2 skin disorders of all types 
including rash (not otherwise specified), dry skin, dermatitis acneiform, pruritus, skin 
chapping, and palmar-plantar erythrodysaesesthia (n=3), were common; however, no 
Grade 3/4 acneiform or other rash was seen. Nausea, decreased appetite and 
vomiting were also reported frequently but without a clear relation to dose. No 
clinically significant LVEF decline or evidence of ophthalmic toxicity was observed. 
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In 10 patients (30%) treatment with S-222611 was associated with unconjugated 
hyperbilirubinaemia, Grade 1 or 2 in all but one case, unaccompanied by 
abnormalities of other liver function or evidence of hemolysis.  Analysis of the 
germline UGT1A1 locus in one of these patients revealed the heterozygous *1/*28 
genotype, which is not associated with a Gilbert’s syndrome phenotype as an 
explanation for unconjugated hyperbilirubinaemia (8).  This hyperbilirubinaemia was 
generally self-limiting and did not result in discontinuation of dosing. 
Two DLTs occurred during the first 3 weeks of daily treatment, one each at dose 
levels of 1200 & 1600mg.  At 1200mg, a 77-year-old woman with HER2-positive 
breast cancer developed intolerable Grade 2 rash.  At 1600mg, a 38-year-old woman 
with non-small cell lung cancer developed diarrhoea (Grade 3) despite symptomatic 
treatment.  Both DLTs resolved promptly on dose interruption and, after re-challenge 
at a reduced dose of 400mg daily, the patients tolerated treatment well.  Although no 
more than one DLT was reported in any cohort, dose escalation beyond 1600mg was 
not undertaken, due to acquired safety and pharmacokinetic data.  These data 
contributed to the selection of a dose of 800mg for evaluation in further trials.   
Pharmacokinetic analysis 
The PK parameters after single and repeat doses over the dose range studied are 
shown in Table 3.  After single doses of 800mg, geometric mean values of Cmax were 
greater than expected from the doubling of dose from 400mg, but average 
concentrations (Cav) and AUC over the 24 h dosing interval (AUC0-τ) at steady state 
were approximately dose-proportional. Exposure at 1200mg was similar to that at 
800mg, and at 1600mg was less than that at 800mg (Figure 1).  Median Tmax values 
ranged from 4 to 6h and were independent of dose. The half-life was very consistent 
over the dose range studied, with geometric mean values ranging from 31 to 36h. 
There was no consistent association of drug clearance parameters with weight or 
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surface area (not shown). Based on trough levels, steady state was achieved within 
7 days of repeat dosing. 
Concentrations of the pharmacologically active dealkylated and lactam metabolites of 
S-222611 reflected those of the parent molecule, with AUC values less than 14% 
and 8% (molar basis), respectively, and average half-lives of 45 h and 25 h, 
respectively.   
Antitumour activity 
There were two partial responses (PRs), confirmed on repeat scans two months 
apart, one in a patient with EGFR-positive renal cell carcinoma (RCC) treated at 
200mg, who had previously been treated with sunitinib and everolimus (Figure 2a, 
b); and the other in a patient with EGFR-positive oesophageal carcinoma at 400mg. 
A complete clinical response (CR) was observed in a patient with cutaneous HER2-
positive breast carcinoma, previously treated with lapatinib and trastuzumab, treated 
at 1200mg S-222611 (Figure 2c, d).  Four unconfirmed PRs were seen in patients 
with HER2-positive breast cancer who had previously failed treatment with both 
trastuzumab and lapatinib, and in HER2- and/or EGFR-positive oesophageal 
carcinoma.  Two patients had responses continuing beyond 18 months, and a further 
two (with pancreatic and vaginal adenoid cystic carcinomas) had stable disease for 
more than 18 months (Figure 3). Overall, clinical response or radiological tumour 
shrinkage of >30% was observed in 7 patients (7/33; 21%; Figure 3). Disease 
control rate (CR+PR+SD) was 27% (Figure 3). 
Pharmacodynamic analysis 
Sequential tumour biopsies, collected at baseline and on treatment, were available 
for phosphoprotein analysis (pEGFR, pHER2 and pHER3) from 4 patients (2 
responses, 2 disease progression). Baseline pHER3 expression was high (3+) in 
only one patient (with HER2-amplified breast cancer), and on repeat biopsy after 
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exposure to 1200mg S-222611 this expression fell (1+), and the patient underwent a 
complete clinical response (Figure 2e, f).  
Discussion 
Several drugs targeting ERBB receptors have received regulatory approval, including 
both small molecules (gefitinib, erlotinib, lapatinib) and antibodies (trastuzumab, ado-
trastuzumab, pertuzumab, emtansine, cetuximab, panitumumab).  This trial was 
conducted because the greater potency and broader specificity of S-222611 suggest 
a potential for improvement in clinical efficacy compared with these earlier-
generation drugs.  Some patients seem to benefit from treatment with novel, 
improved ERBB receptor inhibitors despite disease progression on established 
ERBB blockers, suggesting continued dependence on, or addiction to, signaling via 
this pathway in these cancers (9).   
We describe the dose escalation Phase 1 trial of oral S-222611, a reversible inhibitor 
of EGFR, HER2 and HER4, administered daily to patients with tumours over-
expressing EGFR or HER2.  This drug was very well tolerated, with good 
pharmacokinetic properties, and we observed durable efficacy in several tumour 
types, including patients with breast, oesophageal and renal cancers.  These results 
support further development of this small molecule in patients with cancers 
expressing relevant biomarkers.   
The most frequent toxicities seen with S-222611 were diarrhoea, fatigue, rash and 
nausea, with few of Grade 3 and none of Grade 4 severity.  Although an MTD was 
not reached, DLTs of rash in one patient, and diarrhoea in another, were observed in 
separate cohorts.  The toxicities of S-222611 are consistent in nature, but not in 
frequency or severity, with those of first generation ERBB-specific inhibitors (5, 10-
12).  At doses of S-222611 associated with clinical activity, rash requiring systemic 
antibiotics or topical steroids was not seen, and diarrhoea was manageable with 
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symptomatic treatment without dose reduction.  This compares favorably with second 
generation pan-HER inhibitors, which have been associated with rates of grade 3-4 
diarrhoea up to 30%, leading to treatment discontinuation in 6-14% of patients (13, 
14). No significant decline in left ventricular ejection fraction occurred despite the 
known expression of HER2 on cardiac myocytes (15).  Observed efficacy, 
pharmacodynamic and pharmacokinetic data informed a selection of 800mg 
administered once daily as the recommended dose for Phase 2 study.  The 
tolerability of prolonged S-222611 dosing at clinically effective doses, particularly with 
respect to fatigue and to the on-target EGFR-mediated toxicities of rash and 
diarrhoea, represent a contrast with first generation drugs. 
PK analysis suggested an approximately dose-proportional relationship up to a dose 
of 800mg daily. PK data suggest that above this dose absorption becomes saturated.  
Trough S-222611 concentrations at steady state with daily doses of 400mg or 
greater exceeded those that inhibit EGFR and HER2 in vitro (manuscript in 
preparation).  All PK parameters displayed relatively high inter-patient variability, as 
seen with other ERBB-targeted tyrosine kinase inhibitors, including erlotinib, gefitinib, 
lapatinib, and afatinib (4, 5, 10-12). An unconjugated hyperbilirubinemia observed in 
a significant minority of patients appears not to be caused by UGT1A1 genotypes 
associated with loss of bilrubin conjugation activity (8); it is possible that S-222611 
competes with bilirubin for hepatocyte transporter-mediated influx.  The terminal 
elimination half-life of S-222611 is consistent with once-daily dosing. The association 
of drug clearance parameters with weight and surface area was poor, supporting the 
use of fixed drug dose administration.  
We observed radiological shrinkage >30% (confirmed and unconfirmed), or clinical 
complete response, in 21% (7/33) of all patients treated at any dose in this trial, 
including patients with HER2-positive breast cancer previously exposed to HER2-
targeting drugs, and patients with HER2-positive or EGFR-expressing oesophageal 
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cancer.  A marked and sustained response was observed in a case of multiply-
pretreated RCC expressing EGFR.  No cases of NSCLC with known activating 
tyrosine kinase domain mutations were included in this trial.  Stable disease for at 
least 6 months occurred in a further two patients, and in total 4 patients remained on 
study drug beyond 12 months.  The clinical benefit rate (response or sustained stable 
disease) was 27%, including unconfirmed responses.  This was despite the fact that 
30% of patients in this trial, including some of those deriving significant clinical 
benefit from S-222611, had previously been exposed to ERBB-targeting therapies.  
The potency and broad specificity of S-222611, potentially providing effective 
blockade of all possible signaling-active ERBB family dimers, may explain the activity 
of this drug, especially in patients previously treated with early-generation ERBB-
targeting drugs (whether small molecules or antibodies). HER3 has impaired kinase 
activity, undergoing phosphorylation only when it is heterodimerized with another 
ERBB receptor (16). Thus levels of pHER3 provide an indication of the effectiveness 
of inhibition across this receptor family. HER3 appears to play a particularly key role 
in HER2-positive breast cancer (17). In this trial a complete clinical response 
occurred in a patient with HER2-amplified breast cancer, coincident with a marked 
reduction in pHER3 expression.    
S-222611 is very well tolerated when administered orally, once daily, even for long 
periods of continuous dosing.  800mg was established as the recommended Phase 2 
dose, with promising antitumour activity in a variety of tumour types expressing 
receptors targeted by this inhibitor. Further study evaluating the efficacy of S-222611 
is in progress. 
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Research in context 
Systematic review: 
We searched PubMed and the American Society of Clinical Oncology virtual meeting 
database for reports published in English between January 1, 2003, and September 
1, 2013, with the terms “EGFR neu receptors”, “receptor, Epidermal Growth Factor”, 
“receptor, erbB-2”, “receptor tyrosine-protein kinase, erbB-4”, “antagonists and 
inhibitors”, and the names of several tyrosine kinase inhibitors in clinical development 
(e.g. afatinib, dacomitinib, neratinib). These agents reversibly or irreversibly inhibit 
the tyrosine kinase domain various members of the ERBB receptor superfamily (1). 
Early trials with drugs in this class did not select patients for target expression, but 
efficacy is improved by targeting only those with tumours driven by mutation or 
overexpression of ERBB receptors (2,3,5,9). 
Interpretation: 
We have conducted a Phase I dose-escalation study of S-222611, the first use of this 
novel inhibitor of EGFR, HER2 and HER4 in cancer patients. There is unmet need 
for new inhibitors of these targets, with increased potency, broader specificity, and 
better-tolerated chronic administration, especially with chronic administration, 
because of the limited efficacy of early-generation therapies in this class. Eligible 
patients had evidence of upregulated tumour ERBB signaling. S-222611 appears 
safe, and associated with manageable toxicities even after chronic dosing. 
Significant efficacy has been demonstrated, and further study of this new drug is 
underway. 
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Table 1 Patient demographics – all treated patients (n=33) 
      n (%) 
Sex  
Male 24 (72.7%) 
Female 9 (27.3%) 
Median age, years (range) 
Primary cancer  
63  (24 - 79) 
Oesophageal/gastric 7 (21.2%) 
Non-small cell lung 5 (15.2%) 
Pancreatic  5 (15.2%) 
Renal 4 (12.1%) 
Breast 3 (  9.1%) 
Other 9 (27.3%) 
ECOG PS at screening  
0   8 (24.2%) 
1 25 (75.8%) 
All prior therapies  
1−2 27 (81.8%) 
>3 6 (18.2%) 
Prior ErbB-targeted therapies  
Yes 10 (30.3%) 
No 23 (69.7%) 
Prior chemotherapy  
0 3 (  9.1%) 
1−2 29 (87.9%) 
>3 1 (  3.0%) 
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Table 2 Treatment-related adverse events (AEs) : AEs reported in 3 or more patients, and all related Grade 3 AEs 
Values shown represent the number (%) of patients; there were no Grade 4 or 5 treatment-related AEs 
 
100 mg/day 
n=5 
200 mg/day 
n=3 
400 mg/day 
n=6 
800 mg/day 
n=6 
1200 mg/day 
n=6 
1600 mg/day 
n=7 
Overall 
n=33 
 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
Diarrhoea 2* 0 2 0 5 0 6 0 6 1 5 2 26 (79)  3  (9) 
Fatigue 4* 1 1 0 4 0 5 0 3 0 3 1 20 (61)  2  (6) 
Rash
†
 2 0 1 0 2 0 4 0 6 0 4 0 19  (58) 0 
Nausea 3 0 1 0 4 0 2 0 4 0 3 0 17 (52) 0 
Decreased 
appetite 
3* 0 1 0 2 0 3 1 3 0 3 0 15 (45)  1  (3) 
Vomiting 1 0 1 0 2 0 2 0 2 0 1 0  9 (27) 0 
Blood bilirubin 
increased 
0 0 0 0 3 0 1 0 1 0 3 1  8  (24)  1  (3) 
Taste 
disturbance
‡
 
2 0 0  0 1  0 1 0 1  0 2 0  7  (21) 0 
Abdominal 
pain** 
1 0 0 0 0 0 3 0 2 0 1 0  7  (21) 0 
Weight 
decreased 
0 0 0 0 1 0 1 0 2 0 1 0  5  (15) 0 
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100 mg/day 
n=5 
200 mg/day 
n=3 
400 mg/day 
n=6 
800 mg/day 
n=6 
1200 mg/day 
n=6 
1600 mg/day 
n=7 
Overall 
n=33 
 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
All 
Grades 
Grade 3 
Lymphopenia 0 0 1  0 1 1 0  0 1  1 1 1  4  (12)  3  (9) 
Dry eye 1 0 1 0 0 0 0 0 2 0 0 0  4  (12) 0 
Constipation 0 0 1  0 0 0 0 0 2 0 1 0  4  (12) 0 
Dyspepsia 1 0 1  0 0 0 0 0 1  0 1 0  4  (12) 0 
Pneumonitis 0 0 0  0 0 0 0  0 0 0 1 1  1  (3)  1  (3) 
Muscular 
weakness 
0 0 0  0 0 0 0  0 0 0 1 1  1  (3)  1  (3) 
GGT increased 0 0 0  0 1 1 0  0 0 0 0 0  1  (3)  1  (3) 
 
* As permitted by the protocol, one patient dose-escalated from 100 to 400 mg daily; these AEs occurred on the higher dose 
† Rash includes rash of all types and the terms dry skin, erythema, skin chapped, dermatits acneiform, pruritus and palmar-plantar erythrodysesthesia  
‡ Taste disturbance includes coded terms dysgeusia and ageusia 
** Abdominal pain includes upper abdominal pain and lower abdominal pain 
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Table 2 Geometric mean (Geometric CV %) pharmacokinetic parameters of S-222611 on Day 1 after single oral administration of 
100, 200, 400, 800, 1200 and 1600mg S-222611 tablets, and at Day 28 (steady state) after 21-day continuous dosing once daily. 
Dose mg 100  200  400  800 1200 1600 
Single dose (Day 1) 
n 5 3 6 6 6 7 
Cmax ng/mL  75.0 (35.6) 63.0 (62.4) 240 (65.5) 703 (32.2) 897 (40.7) 647 (57.7) 
Tmax h 4.0 (4.0, 4.1) 4.0 (4.0, 12.0) 5.1 (4.0, 12.1) 6.0 (4.0, 6.0) 4.1 (2.0, 6.0) 4.1 (4.0, 12.3) 
AUC0-inf ng·h/mL 1600 (27.8) 1670 (40.1) 5050 (46.4) 16400 (38.8) 21500 (41.7)* 14700 (54.1) 
CL/F L/h  62.5 (28.0) 120 (40.3) 79.2 (46.4) 48.7 (38.8) 55.8 (41.8)* 109 (54.1) 
Vz/F L  3130 (26.8) 6120 (37.5) 3520 (37.2) 2340 (30.9) 2870 (42.8)* 4900 (48.5) 
t1/2,z h  34.8 (3.1) 35.4 (3.4) 30.8 (12.6) 33.4 (11.0) 35.7 (23.8)* 31.3 (17.7) 
Steady state (Days 28-29) 
n 3 3 5 5 4 4 
Cmax ng/mL 88.2 (13.9) 112 (32.3) 403 (16.4) 725 (39.8) 591 (51.6) 778 (65.4) 
Tmax h 5.9 (4.2, 6.0) 4.0 (4.0, 6.1) 4.0 (3.8, 6.2) 4.1 (4.0, 11.1) 5.0 (4.0, 6.0) 5.1 (4.0, 6.0) 
AUCng·h/mL 1300 (19.1) 1630 (32.9) 5990 (21.3) 10600 (48.6)** 10200 (54.6) 12300 (52.0) 
Cav ng/mL 53.6 (17.1) 67.8 (32.7) 251 (21.4) 443 (48.5)** 404 (50.0) 512 (56.8) 
FI % 108 (7.8) 104 (5.0) 104 (10.8) 77.9 (43.4)** 79.2 (25.1) 74.4 (73.5) 
Geometric Mean (Geometric CV%) values except Tmax for which median and range are shown.  *n=5; **n= 4 
Abbreviations: Cmax maximum plasma concentration; Tmax time from baseline to Cmax; AUC0-inf area under plasma concentration versus time curve from time zero 
extrapolated to infinity; CL/F apparent total body clearance; Vz/F apparent volume of distribution and t½λz terminal half-life for single dose; AUCτ area under the 
plasma concentration versus time curve during a dosing interval; Cav average plasma concentration during a dosing interval; FI Fluctuation index over a dosing 
interval for repeat dose.  
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Figure Legends 
Figure 1. Geometric mean drug plasma concentration-time profiles of S-222611 after 
single- and multiple-dosing oral administration of 100, 200, 400, 800, 1200 and 
1600mg. 
 
Figure 2. Pre- (a) and post-treatment (b) CT scans showing hilar lymphadenopathy 
(red circle) and pleural metastases (yellow circle) in a patient with renal cell 
carcinoma expressing EGFR, which had previously progressed on sunitinib and 
everolimus. Pre- (c) and post-treatment (d) appearance of cutaneous disease in a 
female with HER2-positive breast cancer who had previously failed treatment with 
trastuzumab and lapatinib; baseline (e) and post-cycle 1 (f) tumour biopsies from the 
same patient showing downregulation of pHER3. 
 
Figure 3. Patients treated at each dose level, showing biomarker upregulation in 
tumour samples, time on treatment, and best response by RECIST. 
